10 Best Performing Penny Stocks So Far in 2025

8. CytomX Therapeutics, Inc. (NASDAQ:CTMX)

Year-to-Date Performance: 129.25%

Share Price: $2.43

Number of Hedge Fund Holders: 15

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is one of the best-performing penny stocks so far in 2025. On May 12, CytomX Therapeutics, Inc. (NASDAQ:CTMX) shared encouraging interim Phase 1 data for CX-2051, its EpCAM PROBODY ADC candidate, in advanced, late-line colorectal cancer (CRC).

The findings were based on data collected as of April 7, 2025, from the ongoing CTMX-2051-101 Phase 1 study.

As part of this trial, 23 patients were treated with three different doses. These were the 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg doses. Out of these, 18 patients could be assessed, having had a minimum of one post-baseline tumor assessment as of the data cutoff.

According to the report by CytomX Therapeutics, Inc. (NASDAQ:CTMX), CX-2051 was generally well-tolerated with manageable side effects, with no observed dose-limiting toxicities.

CX-2051 is showing strong and durable anti-tumor activity in late-line metastatic CRC, which is a very hard tumor to treat. Sean McCarthy, D. Phil, CEO and chairman of CytomX Therapeutics, Inc. (NASDAQ:CTMX), noted that this is an area that has high unmet needs.

Overall, CX-2051 has been generally safe, which highlights the potential of CytomX Therapeutics, Inc.’s (NASDAQ:CTMX) special PROBODY masking technology.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is a clinical-stage, oncology-focused biopharmaceutical company focused on developing masked biologics that conditionally activate in the tumor microenvironment.